100 ml Test Kit - Pearls 100u./Reagent 1x7,5mL / Adjusters mL (lyophilized) 2x4mL (commercially available) Product Name: IGF-I - IMMULITE (Anvisa Record No. 10345161109) /// Affected Model (s) / Solution 1x30mL /// Affected lot: 411 /// Product risk class: II. 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 Siemens Healthcare Diagnósticos S.A.; Siemens Healthcare Diagnostics Products Ltd.. 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    1896
  • 날짜
    2016-05-11
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    AT.
  • 원인
    Siemens healthcare diagnostics has identified that incubation prior to the processing of patient samples takes 24 minutes in the immulite / immulite 1000 system so that the pretreatment solution reaches full equilibrium when using the pre-treatment solution (lgfa) lot 055 , contained in the immulite 2000 igf-i kit, batch 411. if patient samples are processed before full equilibrium is reached, an underestimate recovery of -36% may occur. however, if the sample is incubated for more than 24 minutes before the test, an underestimate will not be observed. there is a potential for a falsely suppressed igf-i value that may delay the diagnosis for acromegaly and / or potential pharmacological treatment to normalize serum igf-i. the impact of clinical potential is mitigated by serum igf-i monitoring as well as by correlation of serum growth hormone dosages and clinical presentation. quality controls will not detect this problem.
  • 조치
    Field classification: letter to the client /// Field action code: IMC 16-05 /// Recommendations to users and patients: ensure that the pre-treatment solution is incubated with the patient sample for at least 24 minutes prior to processing in the IMMULITE / IMMULITE 1000 systems.